Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

IMS Health (IMS) Prices Upsized Offering Of Senior Notes

Published 09/14/2016, 11:14 PM

IMS Health Holdings, Inc. (NYSE:IMS) announced the pricing of a senior notes offering worth $1.75 billion. The offering consists of $1.05 billion of U.S. dollar notes and €625 million of euro notes. The notes will be issued by its wholly owned subsidiary, IMS Health Inc.

The $1.05 billion U.S. dollar notes will bear interest at a rate of 5.0% and the €625 million euro notes will bear interest at a rate of 3.5%. Both would pay interest semi-annually in arrears on Apr 15 and Oct 15 of each year beginning on Apr 15, 2017. The U.S. dollar notes will mature on Oct 15, 2026 while the euro notes will mature on Oct 15, 2024.

The offering was upsized from a previously announced $1.5 billion equivalent aggregate principal amount. The net proceeds from the notes offering will primarily go toward the previously announced proposed merger between IMS Health and Quintiles Transnational Holdings Inc. (NYSE:Q) .

The merger, originally announced in May, would be named Quintiles IMS Holdings, Inc. Under the terms of the merger agreement, IMS Health shareholders will receive a fixed exchange ratio of 0.384 shares of the Quintiles common stock for each share of the IMS Health common stock. Upon completion of the merger, IMS Health shareholders will own approximately 51.4% of the shares of the combined company and Quintiles shareholders will own approximately 48.6%.

IMS Health is a leading global information and technology services company catering to clients in the healthcare industry.

Zacks Rank & Key Picks

Currently, IMS Health Holdings carries a Zacks Rank #3 (Hold). Better-ranked stocks in the broader medical sector include RadNet, Inc. (NASDAQ:RDNT) and US Physical Therapy Inc. (NYSE:USPH) . Notably, both the stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Confidential from Zacks

Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>



QUINTILES TRANS (Q): Free Stock Analysis Report

RADNET INC (RDNT): Free Stock Analysis Report

US PHYSICAL THR (USPH): Free Stock Analysis Report

IMS HEALTH HLDG (IMS): Free Stock Analysis Report

Original post

Zacks Investment Research

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.